These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 1300783)

  • 21. [Inflammatory carcinoma of the breast: the immunological findings].
    Sacco R; Carpino A; Bolognini S; Corapi A; Colace R; Bianca T
    Minerva Chir; 1994 Dec; 49(12):1351-6. PubMed ID: 7746461
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Various immunological and immunomorphological changes in patients with breast cancer after interferon administration].
    Mkrtchian LN; Galstian AM; Ovanesbekova TG; Ter-Pogosian ZR; Kuznetsov VP
    Vopr Onkol; 1986; 32(10):25-31. PubMed ID: 3490716
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Changes of the cellular immunity tests during the evolution of Hodgkin's disease.
    Răileanu-Moţoiu I; Dumitrescu A; Costescu M; Mocanu N; Berceanu S
    Med Interne; 1983; 21(3):203-15. PubMed ID: 6665494
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Effect of tamoxifen on parameters of cell-mediated immunity in postmenopausal patients with breast carcinoma].
    Mallmann P; Krebs D
    Zentralbl Gynakol; 1991; 113(12):689-96. PubMed ID: 1927118
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Immunity and hypersensitivity in Hodgkin's lymphoma].
    Leoni P; Marchegiani G; Montillo M; Centurioni R; Montroni M; Danieli G
    Minerva Med; 1982 May; 73(20):1361-9. PubMed ID: 6210855
    [No Abstract]   [Full Text] [Related]  

  • 26. [Micromodification of the leukocyte adherence inhibition test for cancer patients].
    Kharkevich DD; Tabagari DZ; Savinov AIu
    Vopr Onkol; 1985; 31(7):17-21. PubMed ID: 3895734
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Autologous rosette-forming capacity of T-lymphocytes in Hodgkin's disease.
    Bodolay E; Berényi E; Sonkoly I; Szegedi G
    Acta Med Hung; 1984; 41(2-3):113-9. PubMed ID: 6611543
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment with autologous antigen-presenting cells activated with the HER-2 based antigen Lapuleucel-T: results of a phase I study in immunologic and clinical activity in HER-2 overexpressing breast cancer.
    Park JW; Melisko ME; Esserman LJ; Jones LA; Wollan JB; Sims R
    J Clin Oncol; 2007 Aug; 25(24):3680-7. PubMed ID: 17704416
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Circulating immune complexes and immunologic reactivity in breast cancer].
    Bilynskiĭ BT; Loginskiĭ VE; Fetsich TG
    Eksp Onkol; 1984; 6(3):50-2. PubMed ID: 6333978
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of pre-existent immunity in patients with primary breast cancer: molecular and cellular assays to quantify antigen-specific T lymphocytes in peripheral blood mononuclear cells.
    Rentzsch C; Kayser S; Stumm S; Watermann I; Walter S; Stevanoviç S; Wallwiener D; Gückel B
    Clin Cancer Res; 2003 Oct; 9(12):4376-86. PubMed ID: 14555509
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunohistochemical analysis of the distribution of lymphocyte subpopulations in Hodgkin's disease.
    Borowitz MJ; Croker BP; Metzgar RS
    Cancer Treat Rep; 1982 Apr; 66(4):667-74. PubMed ID: 6210433
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunodeficiencies in Hodgkin's disease. Part I: T cell-mediated immunity.
    Gupta S
    Clin Bull; 1981; 11(2):58-65. PubMed ID: 6459892
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients.
    Peoples GE; Gurney JM; Hueman MT; Woll MM; Ryan GB; Storrer CE; Fisher C; Shriver CD; Ioannides CG; Ponniah S
    J Clin Oncol; 2005 Oct; 23(30):7536-45. PubMed ID: 16157940
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunodeficiencies in Hodgkin's Disease. Part II: B cell immunity, complement systems and phagocytic cell systems.
    Gupta S
    Clin Bull; 1981; 11(3):110-9. PubMed ID: 7039866
    [No Abstract]   [Full Text] [Related]  

  • 35. [Hodgkin's disease: relapse after 16 years of continuous remission].
    Rössle A; Bancalari G; Fahrenkrog A; Cerón M; Dujisin K; Saldivia V; Agurto M
    Rev Med Chil; 1994 Jul; 122(7):812-4. PubMed ID: 7732233
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Blastogenic transformation of lymphocytes following phytohaemagglutinin treatment in vitro in malignant lymphomas. I. Hodgkin's disease. (Correlation with immunity response of the cellular type and with the clinical status).
    Libánský J; Lukásová M; Pinosová I
    Neoplasma; 1973; 20(1):51-60. PubMed ID: 4702205
    [No Abstract]   [Full Text] [Related]  

  • 37. Specificity of tumor antigen recognition by T-lymphocytes in the leukocyte adherence inhibition (LAI) assay in patients with breast cancer.
    Tsang PH; Holland JF; Bekesi JG
    J Clin Lab Immunol; 1982 Dec; 9(3):151-7. PubMed ID: 6762442
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immune status of untreated patients with Hodgkin's disease and prognosis.
    Björkholm M; Wedelin C; Holm G; Ogenstad S; Johansson B; Mellstedt H
    Cancer Treat Rep; 1982 Apr; 66(4):701-9. PubMed ID: 7074640
    [TBL] [Abstract][Full Text] [Related]  

  • 39. B lymphocytes in untreated patients with malignant lymphoma and Hodgkin's disease.
    Gajl-Peczalska KJ; Hansen JA; Bloomfield CD; Good RA
    J Clin Invest; 1973 Dec; 52(12):3064-73. PubMed ID: 4201499
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Immunologic changes in patients with Hodgkin's disease in clinical remission and recurrence].
    Ares BR; Sasiain MD; Brezavscek DM; Fejes M; Bachmann AE
    Medicina (B Aires); 1981; 41(3):287-92. PubMed ID: 6275237
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.